BioSpace News Archive

Halberd Corporation’s Covid research has led to a scientific article titled, “A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant.” The article has been peer reviewed and accepted for publication, but has not yet been published.

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced its conference schedule for December 2022.

Takeda Canada Inc. is pleased to announce that the Canada’s Drug and Health Technology Agency (CADTH) Canadian Drug Expert Committee (CDEC) recommends LIVTENCITY ™ (maribavir) for public reimbursement.

WISE Cortical Strip is the first cortical strip embedding the electrodes in a highly compliant thin film of silicone to receive FDA clearance.

Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 11,510,992, entitled Compositions and Methods for the Treatment of Viral Infections, for CD388, a highly potent, long-acting drug-Fc conjugate (DFC) designed to achieve universal prevention of seasonal and pandemic influenza.

Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced it has raised $25 million in a Series C financing.

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces interim clinical trial results from the company’s Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment for Ewing sarcoma and FET-rearranged sarcomas.

Inozyme Pharma, Inc. today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the BofA Securities Biotech SMID Cap Conference on Thursday, December 8, 2022, from 8:00-8:30am ET.

Kura Oncology, Inc. today announced that it will host an investor event featuring members of the Kura management team and investigators from KOMET-001, a Phase 1/2 clinical trial of ziftomenib, the Company’s potent and selective menin inhibitor.

Adaptive Biotechnologies Corporation today announced the launch of its clonoSEQ® Assay to detect minimal residual disease (MRD) in blood for patients with diffuse large B-cell lymphoma (DLBCL).